NeuroVive Pharma recruits first patient in CIRCUS study
In the study, NeuroVive is evaluating the advanced CicloMulsion cremophor-free IV cyclosporine formulation in 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.